Related Experiment Video
Updated: Jan 24, 2026

In Vitro Polymerization of F-actin on Early Endosomes
Published on: August 28, 2017
PTEN reduces endosomal PtdIns(4,5)P2 in a phosphatase-independent manner via a PLC pathway
Virginie E Mondin1, Khaled Ben El Kadhi1, Clothilde Cauvin2,3
1Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Canada.
Abstract:
The tumor suppressor PTEN dephosphorylates PtdIns(3,4,5)P3 into PtdIns(4,5)P2 Here, we make the unexpected discovery that in Drosophila melanogaster PTEN reduces PtdIns(4,5)P2 levels on endosomes, independently of its phosphatase activity. This new PTEN function requires the enzymatic action of dPLCXD, an atypical phospholipase C. Importantly, we discovered that this novel PTEN/dPLCXD pathway can compensate for depletion of dOCRL, a PtdIns(4,5)P2 phosphatase. Mutation of OCRL1, the human orthologue of dOCRL, causes oculocerebrorenal Lowe syndrome, a rare multisystemic genetic disease. Both OCRL1 and dOCRL loss have been shown to promote accumulation of PtdIns(4,5)P2 on endosomes and cytokinesis defects. Here, we show that PTEN or dPLCXD overexpression prevents these defects. In addition, we found that chemical activation of this pathway restores normal cytokinesis in human Lowe syndrome cells and rescues OCRL phenotypes in a zebrafish Lowe syndrome model. Our findings identify a novel PTEN/dPLCXD pathway that controls PtdIns(4,5)P2 levels on endosomes. They also point to a potential new strategy for the treatment of Lowe syndrome.
Insights
The tumor suppressor PTEN unexpectedly reduces endosomal phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) levels via phospholipase C, independent of its phosphatase activity. This pathway offers a potential therapeutic strategy for Lowe syndrome.
Area of Science:
- Cell Biology
- Biochemistry
- Genetics
Background:
- The tumor suppressor PTEN normally dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) to PtdIns(4,5)P2.
- Loss of OCRL1, the human orthologue of dOCRL, causes oculocerebrorenal Lowe syndrome, characterized by PtdIns(4,5)P2 accumulation and cytokinesis defects.
Purpose of the Study:
- To investigate a novel function of PTEN in regulating endosomal PtdIns(4,5)P2 levels.
- To identify potential therapeutic targets for Lowe syndrome.
Main Methods:
- Utilized *Drosophila melanogaster* as a model organism.
- Investigated the enzymatic activity of dPLCXD and its interaction with PTEN.
- Examined the effects of PTEN and dPLCXD overexpression on PtdIns(4,5)P2 levels and cytokinesis.
- Tested chemical activation of the pathway in human Lowe syndrome cells and a zebrafish model.
Main Results:
- Discovered PTEN reduces endosomal PtdIns(4,5)P2 independently of its phosphatase activity.
- Identified dPLCXD, an atypical phospholipase C, as essential for this PTEN function.
- Demonstrated that the PTEN/dPLCXD pathway compensates for dOCRL depletion.
- Showed PTEN or dPLCXD overexpression prevents PtdIns(4,5)P2 accumulation and cytokinesis defects.
- Found chemical activation of this pathway restored normal cytokinesis in human cells and rescued zebrafish phenotypes.
Conclusions:
- Identified a novel PTEN/dPLCXD pathway regulating endosomal PtdIns(4,5)P2 levels.
- This pathway provides a potential new therapeutic strategy for Lowe syndrome by targeting PtdIns(4,5)P2 accumulation and associated defects.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Maturation of Endosomes
Changes in location
The maturing endosome moves along microtubules from the periphery of the cell towards the perinuclear region. This movement of the...
Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test:
Hypothesis Test for Test of Independence
H0: The two variables (factors)...
The Early Endosome: Endocytosis of Transferrin

